FIELD: pharmaceuticals.
SUBSTANCE: invention relates to antibody-drug conjugates for the treatment of solid tumors and hematologic malignancies, wherein the linker drug is site-specifically conjugated to an antibody or antigen-binding fragment thereof that binds to the target antigen expressed by the tumor cell, via the inserted cysteine in said antibody or antigen-binding fragment thereof at position 41 of the heavy chain according to Kabat numbering, wherein said drug with a linker is a cytotoxic agent with a linker.
EFFECT: invention widens the range of agents for treating solid tumors.
15 cl, 4 dwg, 7 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| NON-LINEAR SELF-SPLITTING LINKERS AND THEIR CONJUGATES | 2017 |
|
RU2755899C2 |
| METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
| FILTERABLE COMPOSITIONS OF DUOCARMYCIN-CONTAINING ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | 2019 |
|
RU2774642C1 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATIONS | 2007 |
|
RU2639543C9 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| “CYSTEINE-MODIFIED ANTIBODY-DRUG” CONJUGATE AND ITS PRODUCTION METHOD | 2017 |
|
RU2762594C2 |
